Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients
Lonza and Human Genome Sciences Sign Manufacturing Agreement
11:55 PM MDT | July 12, 2010 | Deepti Ramesh
Lonza says it has entered into an agreement with Human Genome Sciences (HGS; Rockville, MD) for the future commercial supply of Benlysta (belimumab), which is currently under regulatory review in the U.S. and Europe as a potential new treatment for systemic lupus erythematosus (SLE). Benlysta is being developed by HGS and GlaxoSmithKline (GSK; London) under a co-development and commercialization agreement entered into in 2006. GSK submitted a marketing authorization application last month to the European Medicines Agency, seeking approval to market belimumab in...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee